Update on PAT-DX1 GMP specification testing

Patrys Limited (ASX:PAB) has provided an update on the GMP manufacturing run of PAT-DX1. The Company's Contract Development Manufacturing Organization (CDMO) has informed that the Quality Assurance and Quality Control approvals for the revised specification testing protocols are pending, delaying the completion of final product testing. The specification testing for the drug substance from the recent manufacturing run is now expected to be completed in the first half of October 2024. Delays in this testing directly impact the commencement of clinical development activities for PAT-DX1.

Executive Commentary on PAT-DX1 GMP specification testing update

The Quality Assurance and Quality Control approvals for the revised specification testing protocols are pending, and we have been advised that the final product testing for PAT-DX1 is now expected to be completed in the first half of October 2024. Delays in this process directly impact the commencement of clinical development activities for PAT-DX1. We will continue to monitor the situation closely and provide further updates as necessary.

Summary of PAT-DX1 GMP specification testing update

Patrys Limited (ASX:PAB) has provided an update on the GMP manufacturing run of PAT-DX1, indicating that the specification testing for the drug substance is now expected to be completed in the first half of October 2024. Delays in this testing directly impact the commencement of clinical development activities for PAT-DX1. The company will continue to monitor the situation closely and provide further updates as necessary. Patrys' focus on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers remains unchanged, and the company's ambitions to target multiple types of cancer with minimal impact on normal, healthy cells continue to guide its corporate strategy.